Moffitt Cancer Center's planning and evaluation of research activities encompass 3 internal and 1 external advisory bodies, as well as ad hoc consultants as needed. Moffitt requests $75,000 to support a portion of these activities, including $70,000 in the category of Consultant Costs and $5,000 in the category of Other Expenses. All advisory bodies report to the Center Director. Each Associate Center Director meets at least monthly with the Center Director and together, they take a lead role in overseeing the planning and evaluation process. These advisory bodies have successfully guided the rapid growth of research over the past decade, and the requested support will continue to enhance these efforts. Moffitt's external advisory board, the Council of Scientific Advisors, reviews the Center's scientific progress in terms of the CCSG by evaluating the research programs, shared resources, scientific and institutional accomplishments, and future plans for sustaining and increasing research growth. It also evaluates the annual research accomplishments relative to the state mandate and reports its findings to the Center's Board of Directors and state officials. Ad hoc advisors advise Moffitt on refining strategic research areas, evaluating its methods, and suggest ways to better organize specific efforts. Moffitt also requests funds for the Center's annual Scientific Retreat. The all day event pulls together faculty, postdoctoral fellows, and students to showcase research from all areas (basic, population, clinical investigations, and translational) and includes an outside keynote speaker.

Public Health Relevance

;

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-15
Application #
8495972
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$42,817
Indirect Cost
$17,406
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612
Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53
Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303
Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73
Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :
Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880
Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029
Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96

Showing the most recent 10 out of 974 publications